WELLBUTRIN XL is indicated for the prevention of seasonal major depressive episodes in patients with seasonal affective disorder (SAD) who have had at least one prior episode. The treatment of seasonal major depressive episodes is discussed in more detail in \[see 14.1\].

### 14.1 Clinical Studies

Bupropion was evaluated in a placebo-controlled, randomized, double-blind trial with 300 mg/day of bupropion HCl immediate-release or placebo in adult patients with major depressive disorder (MDD) with seasonal affective disorder (SAD). Overall, 1301 patients participated, mostly female (77%). The treatment discontinuation rates were 7.9% for placebo and 8.4% for bupropion HCl immediate-release. The most common adverse reactions associated with bupropion HCl immediate-release were nausea, vomiting, and diarrhea.

### 14.2 Pharmacokinetics

Bupropion has a plasma elimination half-life of approximately 9 hours. The clearance of bupropion is primarily hepatic, and it is metabolized by cytochrome P450 2C9 and 1A2. The major metabolite of bupropion is nortriptyline (NTS), which is a tricyclic antidepressant.

### 14.3 frighten (4, 5.3, 7.3)

To minimize the risk of seizure, increase the dose gradually. Discontinue if seizure occurs.